47P Safety and efficacy evaluation of long-course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer: Intermediate results of a multicenter, phase II study

Z. Yang,J. Gao,X. Zhang,G. Wu, W. Deng,Y. Liu,J. Zhang,G. Chen, R. Xu,J. Han,A. Li, G. Liu,Y. Sun,D. Kong,Z. Bai,H. Yao,Z. Zhang

Annals of Oncology（2022）

引用 0|浏览2

暂无评分

摘要

Long course radiotherapy plus neoadjuvant chemotherapy followed by resection (total mesorectal excision, TME) has accepted widespread recognized in the treatment of locally advanced rectal cancer (LARC). Long course (neoadjuvant chemoradiotherapy, NCRT) plus tislelizumab (a PD-1 inhibitor) followed by TME for LARC might bring better downstaging effect and reduce the risk of distant relapse.

查看译文

关键词

advanced mesorectal cancer,neoadjuvant chemoradiotherapy,total mesorectal excision,tislelizumab,long-course

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要